Search Results 141-150 of 17146 for egfr

  1. Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). - Mayo Clinic

    ... (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC. Participation eligibility. Participant eligibility includes age ...

  2. A Study To Evaluate The Safety, Tolerability, And Effects On Blood And Urine Markers Of Single Ascending Dose Of GSK4771261 In Healthy Participants And Participants With Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

    eGFR >=30 mL/min/1.73m^2 (based on the CKD-EPI 2021 eGFR equation) and, in the clinical judgement of the investigator, the participant: has been clinically ...

  3. Publications - Cris M. Ida, M.D. - Mayo Clinic

    EGFR transcript variants: Potential diagnostic biomarker for glioblastoma, IDH-wildtype? J Neuropathol Exp Neurol. 2025 Nov 1; 84 (11):1059-1062. View PubMed ...

  4. Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease - Mayo Clinic

    Participation eligibility · Diabetes mellitus (on anti-diabetes drug therapy). · Age 40-80 years old. · Estimated glomerular filtration rate (eGFR) 25-55 ml/min/ ...

  5. Small Cell Lung Cancer Clinical Trials - Mayo Clinic Research

    ... EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, and RET) and that has progressed on or after 1 or more kinase inhibitors and platinum-based chemotherapy.

  6. Kidney diet (renal diet) - Mayo Clinic

    Foods in a kidney diet have lower amounts of sodium, protein, potassium, or phosphorus. There are many foods you can still enjoy! Here are some kidney-friendly ...

  7. Vamsi Velcheti, M.D. - Doctors and Medical Staff - Mayo Clinic

    Targeted Therapies: Development and clinical application of novel therapeutics for oncogene-driven lung cancers, including EGFR, ALK, KRAS, MET, ROS1, RET ...

  8. Serial Blood and Urine Monitoring Study in Kidney Transplant Recipients - Mayo Clinic

    ... EGFR, IFN-gamma, TSP-1, and IL-10 in urine (Ur) samples were studied using QRT-PCR. Ninety-five KTP and 111 Ur samples were evaluated. Patients (Pts) were ...

  9. Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin for First-Line Treatment of Patients With Advanced NSCLC Without Actionable Genomic Alterations - Mayo Clinic

    ... EGFR mutations, and ALK and ROS1 rearrangements). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and ...

  10. Cardiac Catheterization Clinical Trials - Mayo Clinic Research

    ... [eGFR] <30 or on dialysis). This is a multicenter randomized controlled trial with a target randomization of ~1000 patients with advanced CKD and at least ...